Development of biosimilars in an era of oncologic drug shortages
Edward Li(Sanden (Japan)), Scott Anderson(Pfizer (United States)), Janakiraman Subramanian(Skin Cancer Foundation), Jason D. McKinley(Pfizer (United States)), Ira Jacobs(Amgen (United States)), Dolca Thomas(Pfizer (United States))
Cited by 41
Related Papers
Histone H3 Methylation by Set2 Directs Deacetylation of Coding Regions by Rpd3S to Suppress Spurious Intragenic Transcription
|Cell|2005|1.3k
Synergistic Function of E2F7 and E2F8 Is Essential for Cell Survival and Embryonic Development
|Developmental Cell|2008|231
Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death
|The Journal of Cell Biology|2017|175
Characterizing the demographics of chronic pain patients in the state of Maine using the Maine all payer claims database
|BMC Public Health|2018|85
Projecting future drug expenditures—2012
|American Journal of Health-System Pharmacy|2012|81